Agnieszka S.
- Country
- Poland
- Department
- NA
Research Overview
- Evaluation of ODM-111 Efficacy and Tolerability in Chronic Pain Management for Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Trial
- Phase 4 Randomized Double-Blind Placebo-Controlled Study on Rimegepant Efficacy and Tolerability in Migraine Prophylaxis for Adults with Inadequate Oral Preventive Response
- Efficacy and Tolerability of Rimegepant in Acute Migraine Treatment for Adults Contraindicated for Triptans: A Phase 4 Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 38 of 111 partner sites.
Specializations
Autoimmune Hair Disorders
The investigator studies alopecia areata to understand mechanisms of hair loss and therapeutic regrowth. Clinical focus includes pediatric and adult populations.
- Immune modulation
- Hair follicle regeneration
- Biologic therapy evaluation
Outcomes aim to improve quality of life for affected individuals.
Migraine and Headache Disorders
Research addresses migraine across chronic, episodic, and pediatric subtypes. Preventive and acute treatment strategies are explored.
- Preventive CGRP antagonists
- Acute triptan alternatives
- Hormonal migraine triggers
- Pediatric dosing considerations
Efficacy metrics include reduction in monthly migraine days.
Diabetic Neuropathic Pain Management
Clinical trials evaluate therapies for diabetic peripheral neuropathic pain. Pain intensity and functional outcomes are primary endpoints.
- Neuropathic pain relief
- Quality of life improvement
- Long‑term safety monitoring
Studies incorporate both adult and geriatric cohorts.
Dermatologic Inflammatory Diseases
The investigator focuses on psoriasis and atopic dermatitis. Severity indices guide therapeutic assessment.
- Biologic agents
- Topical immunomodulators
- Efficacy in moderate to severe disease
- Patient‑reported outcomes
Research supports personalized treatment pathways.
Cannabinoid-based Analgesia
Investigation includes inhaled medical cannabis for chronic pain. Safety and tolerability are systematically recorded.
- THC dose‑response
- Respiratory delivery systems
- Pain score reduction
- Adverse event profiling
Findings contribute to evidence‑based guidelines for cannabinoid use.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.